June 17, 2026 · BriMindInvest Research Team · 12 min read
Small-cap stocks carry more risk — but they also carry more upside. When a $2B company finds product-market fit, it can grow 10x before becoming mid-cap. Here's a screened list of small-cap opportunities from mid-2026, with honest risk ratings — and an important update: several of these names have since grown out of small-cap territory entirely.
Since this list was first published, Reddit (RDDT) has surged to a $34.3B market cap and joins the S&P 500 on August 18, 2026 — it's no longer a small-cap by any definition. IonQ (IONQ) has grown to $18.4B on 287% year-over-year revenue growth. Hims & Hers (HIMS), Archer Aviation (ACHR), and CAVA Group (CAVA) have all crossed into mid-cap territory ($5–9B). Only SoundHound AI (SOUN, $3.3B) remains squarely small-cap today. We're keeping all seven names for continuity but flagging their current market-cap status clearly below — treat this less as a "small-cap" list now and more as a track record of how fast small-caps can re-rate. The Russell 2000 index also hit a record high of 3,068 on August 14, 2026 (up from ~2,050), and IWM's AUM grew to $80.1B while AVUV grew to $29.1B. Source: stockanalysis.com, etfdb.com, AAII fund data, as of 8/14–8/15/26.
Small-cap stocks are publicly traded companies with a market capitalization generally between $300 million and $2 billion. They occupy a distinct investing category from large-caps (S&P 500 names) and micro-caps (below $300M). Key characteristics:
The small-cap premium is one of the most studied phenomena in academic finance. Eugene Fama and Kenneth French's 1992 three-factor model identified small-cap stocks as systematically earning higher returns than large-caps over long periods — roughly 2–3% per year historically.
Why does the premium persist?
| ETF | Ticker | ER | AUM | # Stocks | Index | Profitability Screen | Value Tilt |
|---|---|---|---|---|---|---|---|
| iShares Russell 2000 | IWM | 0.19% | $80B+ | ~2,000 | Russell 2000 | None | None |
| Vanguard Small Cap | VB | 0.05% | $60B+ | ~1,400 | CRSP US Small Cap | Mild | None |
| Avantis US SC Value | AVUV | 0.25% | $29B | ~700 | Proprietary | Strong | Strong |
| iShares S&P 600 | IJR | 0.06% | $25B | ~600 | S&P SmallCap 600 | Yes (4 qtrs profit) | None |
| Schwab US Small-Cap | SCHA | 0.04% | $15B | ~1,750 | Dow Jones US SC | Mild | None |
These two ETFs represent two different philosophies for small-cap investing:
AVUV's edge: it avoids the Russell 2000's structural weakness of including highly unprofitable companies that drag down index returns. By tilting toward profitable value companies, AVUV better captures the academically documented small-cap value premium.
The S&P SmallCap 600 (tracked by IJR) and the Russell 2000 (tracked by IWM) both cover US small-cap stocks, but with a crucial difference: the S&P 600 requires at least four consecutive quarters of positive GAAP earnings for inclusion. This quality screen has meaningful consequences:
The information asymmetry in small caps is enormous. Large-cap stocks like Apple and Microsoft have 30–50 analysts publishing detailed models on them weekly — any public information is instantly priced in. Small-cap stocks with 2–3 analysts covering them are where mispricings persist longest.
Peter Lynch built his legendary track record at Fidelity Magellan by hunting "10-baggers" in small-cap and mid-cap companies before Wall Street paid attention. The principle remains valid: a company that grows from $500M to $5B market cap is a 10-bagger — this is mathematically much harder for Apple to replicate from $3T.
Small-cap stocks have historically been more sensitive to Federal Reserve interest rate changes than large-caps. The mechanism:
Small caps and large caps are not the same bet with different sizes — they have meaningfully different sector exposures:
| Sector | Russell 2000 Weight | S&P 500 Weight | Implication |
|---|---|---|---|
| Financials | ~18% | ~13% | More bank/insurance exposure |
| Healthcare (Biotech) | ~17% | ~12% | Many pre-revenue biotechs |
| Industrials | ~16% | ~8% | Domestic manufacturing tilt |
| Technology | ~13% | ~30% | Far less mega-cap tech |
| Energy | ~6% | ~4% | More small E&P companies |
The lack of mega-cap tech names in the Russell 2000 is both a weakness (missed AI rally) and a valuation advantage — Russell 2000 trades at ~14× forward P/E vs S&P 500's ~22×, reflecting a historically wide valuation gap that could narrow over the coming years.
Revenue growth above 30% YoY is rare for any company — these small-caps are all growing at high velocity, which is what justifies their premium multiples relative to slower-growing large-caps.
SoundHound AI builds conversational voice-AI technology licensed into automaker in-car assistants, restaurant drive-thru ordering systems, and enterprise customer-service applications. NVIDIA holds a strategic equity stake in the company, a signal of confidence in its underlying voice-recognition technology stack.
Trailing revenue growth around 55% remains among the fastest of any stock on this list, and management raised full-year 2026 revenue guidance to $230–260M after a record Q2. Voice AI adoption in customer-facing enterprise settings is still early, giving SoundHound a large addressable market if it can keep winning platform deals.
The company is still not profitable and carries no meaningful forward P/E to value it against. Early-stage enterprise and automotive contracts can be concentrated in a handful of large customers, and SoundHound competes against much larger, better-capitalized players (Amazon, Google, and automakers' own in-house voice teams) that could commoditize the technology.
Archer Aviation is developing the Midnight, an electric vertical takeoff and landing (eVTOL) aircraft designed for short urban air-taxi routes, competing most directly with Joby Aviation. The company has a manufacturing partnership with Stellantis and a launch-customer agreement with United Airlines for future urban routes, and in August 2026 was pursuing an acquisition of Boeing's Wisk Aero and Insitu units.
Archer is one of the furthest-along eVTOL developers on FAA certification milestones, and having an established airline as a launch partner gives it a credible commercial on-ramp. The pending Wisk/Insitu deal would bring in an already-revenue-generating defense and autonomy business, diversifying away from pure pre-commercial air-taxi risk. Analyst buy ratings remain the highest on this list.
This remains a largely pre-commercial-scale company — the ~$5M in quarterly revenue is not yet meaningful relative to the market cap, and there's no forward P/E to anchor a valuation on. Aerospace certification timelines slip routinely, and Archer will likely need to raise additional capital (diluting existing shareholders) as it integrates any acquisition and works toward commercial service. This remains the most speculative, binary-outcome name in the group.
Hims & Hers started as a direct-to-consumer telehealth brand for hair loss and sexual health, then expanded aggressively into GLP-1 weight-loss treatment — offering compounded semaglutide and tirzepatide at a fraction of Novo Nordisk and Eli Lilly's list prices, plus a growing menu of mental health and dermatology subscriptions. Growth has cooled materially since mid-2026 as brand-name manufacturers ramped supply and pricing pressure increased.
The subscription model still produces high repeat revenue, and management has been expanding into brand-name GLP-1 partnerships as an alternative to compounding — a personalization play (dosing, combination formulations) that Big Pharma doesn't offer directly to consumers.
Gross margin has compressed from 82% to 64% and revenue growth has decelerated to roughly 28% TTM (from 52% at the start of 2026) as Lilly and Novo Nordisk ramp direct-to-consumer supply and undercut compounding pricing. Analyst sentiment has turned notably more cautious, with only about a quarter of covering analysts rating the stock a Buy as of mid-August 2026 — a clear downgrade in the story from earlier this year.
Duolingo is the dominant gamified language-learning app, with 100M+ daily active users built almost entirely through organic and viral growth rather than paid acquisition. Its 'Duolingo Max' tier layers large-language-model-powered conversational practice and personalized explanations on top of the free product, and the company has extended the same gamification playbook into math and music courses.
Network effects and brand recognition in language learning are hard to replicate, and the freemium funnel continues converting a growing share of the massive free user base into subscribers. Duolingo Max remains a genuine ARPU expansion lever layered on top of an existing habit-forming product.
Revenue growth has decelerated to roughly 29% year-over-year (from 40% earlier in 2026), and analyst consensus has shifted to mostly Hold with price targets now clustered close to the current share price rather than implying meaningful upside. General-purpose AI chatbots can already hold a passable conversation practice session for free, a longer-term competitive threat if Duolingo's AI features don't stay ahead.
CAVA Group operates a fast-growing Mediterranean fast-casual restaurant chain, positioned in the same 'build-your-bowl' category that made Chipotle a multi-decade compounder. The company has grown well past small-cap territory since this list was first published, and is still in the earlier stages of nationwide unit expansion relative to more mature chains.
CAVA still has a long runway of new-market unit expansion ahead of it — the kind of multi-year growth algorithm that historically rewarded early Chipotle shareholders — and analyst sentiment remains solidly positive.
At roughly 107x forward earnings, CAVA now carries the richest multiple on this list — restaurant stocks rarely sustain such rich valuations for long once same-store-sales growth normalizes, and growth has already cooled from 34% to roughly 27%. Its restaurant-level margin (~26%) is thin relative to the software and platform businesses elsewhere on this list, leaving less cushion against labor and food-cost inflation as it scales into new, less-proven markets.
Reddit, which IPO'd in 2024, monetizes its large first-party forum/discussion dataset two ways: traditional advertising, and data-licensing agreements with AI labs (including Google and OpenAI) that pay to train models on Reddit's conversational data. The stock's rapid re-rating means it is included here only for historical continuity — it has clearly graduated out of the small-cap category.
The AI licensing revenue stream carries roughly 91% gross margin and diversifies Reddit away from being a pure ad-cyclicality play like Snap or Pinterest. Revenue growth of roughly 61% year-over-year and S&P 500 index inclusion (effective Aug 18, 2026) both reflect the scale Reddit has reached.
AI licensing deals are relationship- and contract-dependent — there's no guarantee current terms get renewed on similarly favorable economics once labs have already trained on the historical data. At roughly 30x forward earnings, the stock is cheaper on a multiple basis than it was, but the market cap has grown so much that Reddit is now competing against a completely different, larger peer set than when it was a small-cap.
IonQ is a pure-play quantum computing company using trapped-ion qubit technology, offering access to its systems through cloud partnerships with AWS Braket, Microsoft Azure, and Google Cloud, alongside government and defense research contracts. Revenue has scaled dramatically faster than expected, and the market cap has grown roughly 3.5x since this list was first published.
IonQ posted 287% year-over-year revenue growth in its most recent quarter and raised full-year guidance to $280–290M — a scale of acceleration that has driven strong analyst sentiment (roughly 80%+ Buy ratings) despite the stock no longer being small-cap by any measure.
Quantum computing remains a multi-year-to-decade technology bet — IonQ still has no meaningful P/E to value it against, and faces well-funded competitors (IBM, Google, Rigetti) pursuing different qubit architectures. Analyst price targets show unusually wide dispersion (roughly 46% to over 100% implied upside depending on source), a sign of genuine disagreement about how to value the growth.
If you prefer broad small-cap exposure without picking individual winners, these ETFs cover the spectrum from passive index to factor-informed quality:
The benchmark small-cap index fund; holds all 2,000 Russell 2000 companies; high liquidity with tight spreads
Cheapest Russell 2000 exposure; identical index to IWM at lower cost; slightly less liquid
Tracks S&P 600 which applies quality screens; excludes the weakest small-caps; historically stronger risk-adjusted returns than Russell 2000
Factor-based; targets small-caps with high profitability and low valuation; academic evidence for long-run outperformance; best for buy-and-hold factor investors
Small caps are most appropriate for investors with 5–10+ year time horizons who can tolerate higher volatility in exchange for the historically documented premium. Here's the decision framework:
Get AI prediction signals, unlimited stock comparisons, portfolio analytics, and personalized watchlists — free for 14 days, no credit card required.
14-day free trial · No credit card required · Cancel anytime
Not ready to sign up? Get one free email a week instead.